Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Helius Medical Technologies, Inc.

< Previous 1 2 Next >
Helius Medical Technologies, Inc. Announces First Reimbursement by A Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $3.7 Million Gross Proceeds Priced At-the-Market
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. Announces Strong Enrollment of its Stroke Pivotal Study Exceeding Initial Target
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Announces First Portable Neuromodulation Stimulator (PoNS®) System Sale to the Veterans Affairs (VA) Healthcare System
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. Announces Exploration of Strategic Alternatives
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. Announces Reimbursement Payment Determination Updates from CMS for its Portable Neuromodulation Stimulator (PoNS®) Controller and Mouthpiece
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. Reports Second Quarter 2024 Financial Results
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. to Release Second Quarter 2024 Financial Results on August 12, 2024
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. Completes Site Participation Enrollment for its U.S. Registrational Program in Stroke
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. Announces Third-Party Reimbursement for PoNS® from Major Insurance Carrier
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies to Exhibit at 2024 CMSC Annual Meeting, Marking a Year of Achievements: Making PoNS More Available to People with MS
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. Announces PoNS® Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. Reports First Quarter 2024 Financial Results
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. Announces Preliminary CMS Payment Determination of Reimbursement for Portable Neuromodulation Stimulator (PoNS®)
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Booth and Special Event at APTA Combined Sections Meeting Will Highlight Physical Therapists’ Ability to Customize PoNS Therapy® to Improve Gait in People with MS
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Tickers HSDT
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.